Multifunctional sirna nanoparticles for AML therapy

Ended Definitive Contract Awarded Last action

Contract number
HHSN261201000051C
Awardee
Awarding agency
Obligated
$200,000

Award facts

Contract value 100% obligated
$200,000.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
Total Small Business
Competition
Full and Open Competition after exclusion of sources · 18 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Columbus, OH 43220, USA
Research
SBIR Program Phase I Action

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action 1 $0
Original award $200,000

About this award

This is a $200,000.00 Small Business Innovation Research (SBIR) Program Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Nanomaterial Innovation LTD, a woman-owned limited liability company. The contract is for the development of "MULTIFUNCTIONAL SIRNA NANOPARTICLES FOR AML THERAPY", which aligns with NCI's research focus on cancer therapeutics. The contract has a firm fixed price pricing type and was awarded on September 24, 2010 with a final completion date of August 31, 2011.

Quick answers

Who was awarded contract HHSN261201000051C?

HHSN261201000051C was awarded to Nanomaterial Innovation LTD by National Cancer Institute (National Institutes of Health) on September 24, 2010.

How much is contract HHSN261201000051C worth?

The government has obligated $200,000 on HHSN261201000051C.

Was contract HHSN261201000051C competed?

The extent of competition for HHSN261201000051C was full and open competition after exclusion of sources. The government received 18 offers. It was set aside: Total Small Business.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award